Abiomed bids to buy out partnership:
This article was originally published in Clinica
Abiomed has offered to pay $10,000 per unit for each of the 135 outstanding units of the Abiomed Limited Partnership. If accepted, the offer will reduce or eliminate the company's royalty obligations on sales of its BVS-5000 and SupraCor temporary cardiac support systems. The original annual royalty of 5.5% on product revenues has already been reduced to 4.9% through a 10.9% ownership in the limited partnership. The limited partners have until July 25th, 1995, to accept the offer.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.